Psyched Wellness presented its proprietary extract of the Amanita Muscaria mushroom, AME-1, to Health Canada representatives to discuss the evidence required in support of a Class...
MYND has received the funding that will go towards its research and development into the effects of psilocybin for treating brain and central nervous system diseases.
The clinical trial is aiming to understand how psilocybin alters brain function in order to improve treatment options for mental illness.
The US Food and Drug Administration (FDA) has given authorisation for a Phase II clinical trial to evaluate psychedelic-assisted psychotherapy for frontline clinicians who are experiencing...
Findings from a new study give insight into how psychedelic substances may relieve symptoms of mental health conditions.
In a bid to help bring DMT and 5-MeO-DMT to patients, Biomind Labs has completed the development of its novel nasal gel delivery system.
A new study has been launched to investigate the effects of LSD microdosing on sleep and cognitive measures.
For the multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX) sponsored by MAPS, Numinus will manage two new clinics in Montreal and Vancouver.
New data from the Aquilino Cancer Center Study has shown the safety and feasibility of psilocybin therapy for the treatment of depression in cancer patients.
